Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Development of antivirals: medicinal chemistry at the beginning of the process¿and beyond

  • Peréz-Pérez, María-Jesús
The role of medicinal chemistry in drug discovery is crucial but there is significant discussion these days about how far medicinal chemists should be involved in the development process.1 The advances of the different disciplines accompanying drug discovery besides medicinal chemistry itself such as molecular biology, computational chemistry, pharmacokinetics and metabolism studies among others, have increased the challenges to be faced by medicinal chemists. Antiviral drug development has special characteristics when compared to other therapeutic fields in drug discovery. As an example, in a recent review article asking where do recent small molecule clinical development candidates come from,2 it is indicated that phenotypic screening is still one of the main source of antivirals while for other therapeutic areas target-based or fragment-based screening are becoming more relevant. Once a hit with antiviral properties has been identified, its optimization to become a lead is a multiparameter process, that can also be determined by the mechanism of action of the compound. Recent selected examples of the development of antivirals from the literature will be used to highlight this process. In addition, our own experience in triazolopyrimidines as inhibitors of CHIKV replication will be presented to illustrate how proactive and collaborative efforts among academic groups can lead to the identification and optimization of antivirals exploring a new mechanism of action.3-6, Our project in CHIKV inhibitors is financed by a grant from MINECO/FEDER SAF2015-64629-C2-1-R. We also acknowledge the support to REARBOVIR (SAF2016-81856-REDT), a network for antivirals against arboviral diseases
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Protein-ligand complex for structure-based design: impact on the affinity and antitumor activity of new tubulin ligands

  • Bueno, Oskia
  • Estévez-Gallego, Juan
  • Martins, S.
  • Prota, Andrea E.
  • Gago, Federico
  • Gómez-SanJuan, Asier
  • Camarasa Rius, María José
  • Barasoain, Isabel
  • Steinmetz, Michel O.
  • Díaz, José Fernando
  • Liekens, Sandra
  • Peréz-Pérez, María-Jesús
  • Priego, Eva María
Resumen del trabajo presentado en el XVIII Congreso de la Sociedad Española de Química Terapéutica, celebrado en Salamanca (España), del 23 al 26 de enero de 2018, Microtubules, made of ¿ß¿tubulin heterodimers, are the key components of the cytoskeleton and play a crucial role in many cellular processes, such as cell motility, morphogenesis and mitosis.[1] Interference with microtubule dynamics induces cell cycle arrest during mitosis and triggers cell death. Compounds that interact with tubulin, especially those binding at the colchicine domain, have been deeply investigated as anticancer drugs due to their dual mechanism of action as antimitotics and as vascular disrupting agents.[2,3] Our research group has recently described a new family of colchicine¿domain binders, based on a cyclohexanedione skeleton, with potent antiproliferative activity against tumor and endothelial cells.[4] Moreover, to gain insight into the binding mode of these cyclohexanediones, we have determined the crystal structure of ¿ß¿tubulin in complex with our hit compound (TUB075). Based on this detailed information and by applying the affinity maps program cGRILL, a structurebased synthesis of new cyclohexanedione derivatives has been accomplished with the objective of improving their affinity for tubulin and their antitumor activity. Following this approach, we have obtained new compounds with potent antiproliferative activity against tumor and endothelial cells (IC50=8¿31 nM) and with the highest Kb value reported for compounds binding at the colchicine site in tubulin. Additional studies have shown that they arrest cell cycle at G2/M and disrupt a network of endothelial cells. Moreover they keep antiproliferative activity against cell lines overexpressing P¿gp, further supporting the potential of these compounds., The financial support of the Spanish MINECO (SAF2012‐39760‐C02‐01 and SAF 2015‐64629‐C2‐1‐R), Comunidad de Madrid (BIPEDD2; ref P2010/BMD‐2457) and the COST action CM1407 (to M J. P.P., S.L., M.O.S. and J.F.D.) is sincerely acknowledged